Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact
May 25, 2022

Annual General Meeting 2022

The Annual General Meeting of Vivesto AB, Reg. No. 556332-6676 (”Vivesto” or the ”company”) was held on Wednesday, 25 May 2022.

Documents

  • Minutes Annual General Meeting 2022 – Vivesto AB
    Swedish May 31, 2022
  • Press release – Report from Annual General Meeting in Vivesto AB
    English May 25, 2022
  • Notice Of AGM 2022 Vivesto AB
    English April 25, 2022
  • Postal voting form AGM 2022
    English
  • Proxy form AGM 2022
    English
  • Information about proposed Board members prior to the AGM 2022
    English
  • The Nomination Committee’s proposals AGM 2022
    English
  • The Nomination Committee’s reasoned opinion prior to AGM 2022
    English
  • Teckningsoptionsvillkor serie 2022-2025 – Vivesto AB
    Swedish
  • Annual Report 2021
    English April 28, 2022
  • Ersättningsrapport 2021
    Swedish
  • Revisorsyttrande – ersättning till ledande befattningshavare
    Swedish
  • Press release – The Nomination Committee of Vivesto proposes election of new Board members and new Chairman of the Board
    English April 19, 2022
  • Press release – Nomination Committee appointed for the 2022 Annual General Meeting in Oasmia
    English December 2, 2021

Share this page

Calendar

  • August 12, 2025
    Interim report Q2 2025
  • November 11, 2025
    Interim report Q3 2025
  • February 12, 2026
    Interim report Q4 2025
All events
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents

Now enrolling:

Paccal Vet hemangiosarcoma trial

A clinical study for dogs with splenic hemangiosarcoma

Learn more and take survey to see if you may qualify

 

Take me there
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com